CSL management originally forecast revenue growth of 4-5% and net profit after tax before amortisation (NPATA) growth of 7-10 ...

CSL shares have fallen almost 40% in 2025. Investors are now asking if the worst is already behind the stock. The post Will ...

CSL Behring’s largest-ever trial has ended in failure, as the Australian pharma revealed that its cholesterol efflux enhancer was unable to reduce the risk of heart attacks. The company had been ...

Health editor Michael Smith on CSL’s remarkable story, why investors have fallen out of love with the healthcare giant and what Trump has to do with it. CSL was run like a bureaucracy until 1990 when ...

Macquarie Group Ltd (ASX: MQG) has downgraded CSL Ltd (ASX: CSL) shares. Let's find out why the broker has made the ...

With plasma collection as its stock-in-trade, the struggles of CSL during the coronavirus lockdown were understandable. But a rebound—fueled by a surge in post-pandemic collections and an $11.7 ...

For many investors, the main point of stock picking is to generate higher returns than the overall market. But in ...

On March 27th, global biopharma company CSL opened a new R&D facility in Waltham, Massachusetts. The facility, which will be focused on next-generation vaccines, includes a BSL3 laboratory facility: ...

CSL is a century-old company and a darling among healthcare stocks, having delivered a 15% annual return over the past 10 years. Yet investors are spooked; the stock is down 12% since we upgraded CSL ...

‘BMW CSL’. Collections of letters rarely get more evocative than that, right? This isn’t just a top-of-the-range BMW. The company has only used ‘CSL’ – which now stands for Competition, Sport, ...